BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 15027078)

  • 41. Phase II stopping rules that employ response rates and early progression.
    Goffin JR; Tu D
    J Clin Oncol; 2008 Aug; 26(22):3715-20. PubMed ID: 18669457
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Interval estimation of the proportion ratio under multiple matching.
    Lui KJ
    Stat Med; 2005 Apr; 24(8):1275-85. PubMed ID: 15565736
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A note on P-values under group sequential testing and nonproportional hazards.
    Gillen DL; Emerson SS
    Biometrics; 2005 Jun; 61(2):546-51. PubMed ID: 16011703
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A discrete-continuous mixture quantile function estimator with a practical application to phase II cancer clinical trials.
    Hutson AD
    Stat Med; 2008 May; 27(12):2094-109. PubMed ID: 18038447
    [TBL] [Abstract][Full Text] [Related]  

  • 45. One- and two-stage designs for stratified phase II clinical trials.
    London WB; Chang MN
    Stat Med; 2005 Sep; 24(17):2597-611. PubMed ID: 16118809
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Design of multi-centre trials with binary response.
    Dragalin V; Fedorov V
    Stat Med; 2006 Aug; 25(16):2701-19. PubMed ID: 16252268
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Conditional and exact tests in crossover trials.
    Patefield M
    J Biopharm Stat; 2000 Feb; 10(1):109-29. PubMed ID: 10709805
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Randomized phase II designs in cancer clinical trials: current status and future directions.
    Lee JJ; Feng L
    J Clin Oncol; 2005 Jul; 23(19):4450-7. PubMed ID: 15994154
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Early stopping for sequential restricted tests of binomial distributions.
    Dambrosia JM; Greenhouse SW
    Biometrics; 1983 Sep; 39(3):695-710. PubMed ID: 6652203
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Bayesian design of single-arm phase II clinical trials with continuous monitoring.
    Johnson VE; Cook JD
    Clin Trials; 2009 Jun; 6(3):217-26. PubMed ID: 19528131
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Predictive probability early termination plans for phase II clinical trials.
    Herson J
    Biometrics; 1979 Dec; 35(4):775-83. PubMed ID: 526523
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Early stopping clinical trials of binomial response with an exact group sequential method.
    Zhao Z
    Stat Med; 2007 Apr; 26(8):1724-9. PubMed ID: 17206748
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Improving the design of phase II trials of cytostatic anticancer agents.
    Stone A; Wheeler C; Barge A
    Contemp Clin Trials; 2007 Feb; 28(2):138-45. PubMed ID: 16843736
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Early stopping rules in clinical trials based on sequential monitoring of serious adverse events.
    Kramar A; Bascoul-Mollevi C
    Med Decis Making; 2009; 29(3):343-50. PubMed ID: 19073996
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A simple and efficient bias-reduced estimator of response probability following a group sequential phase II trial.
    Guo HY; Liu A
    J Biopharm Stat; 2005; 15(5):773-81. PubMed ID: 16078384
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Sample size tables for exact single-stage phase II designs.
    A'Hern RP
    Stat Med; 2001 Mar; 20(6):859-66. PubMed ID: 11252008
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Optimising the design of phase II oncology trials: the importance of randomisation.
    Ratain MJ; Sargent DJ
    Eur J Cancer; 2009 Jan; 45(2):275-80. PubMed ID: 19059773
    [TBL] [Abstract][Full Text] [Related]  

  • 58. An extension of the single threshold design for monitoring efficacy and safety in phase II clinical trials.
    Brutti P; Gubbiotti S; Sambucini V
    Stat Med; 2011 Jun; 30(14):1648-64. PubMed ID: 21520453
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A group sequential adaptive treatment assignment design for proof of concept and dose selection in headache trials.
    Hall DB; Meier U; Diener HC
    Contemp Clin Trials; 2005 Jun; 26(3):349-64. PubMed ID: 15911469
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A two-stage phase II trial design utilizing both primary and secondary endpoints.
    Lin X; Allred R; Andrews G
    Pharm Stat; 2008; 7(2):88-92. PubMed ID: 17252536
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.